Sequential Quantitative SPECT/CT Following Therapeutic Administration of 177Lu DOTATATE In a Patient with Liver Metastases from Neuroendocrine Tumor

Peter Bartenstein, MD
Data courtesy of Ludwig Maximillians University, Munich, Germany
|08/07/2018

A 69-year-old male with intestinal carcinoid tumor with multiple liver metastases, confirmed using 68Ga-DOTATOC PET/CT imaging, was referred for radionuclide therapy with 177Lu DOTATATE. Following administration of the first therapeutic dose of 177Lu DOTATATE, the patient underwent SPECT/CT studies performed at 2, 24, 48, and 72 hours after injection to assess tracer concentration across four time points.